MBL2 (Mannose-binding lectin 2 / mannan-binding lectin) — Research notes

UniProt: P11226 (MBL2_HUMAN). HGNC:6922. Chr 10. 248 aa precursor (chain 21-248).

One-line summary

MBL2 encodes the secreted, liver-derived serum collectin "mannose-binding lectin" (MBL,
mannan-binding protein, MBP-C). It is a Ca2+-dependent C-type lectin pattern-recognition
molecule of innate immunity that recognizes terminal mannose/GlcNAc/fucose on microbial
surfaces and, via associated MASP serine proteases, initiates the LECTIN PATHWAY of complement.

Architecture (from UniProt P11226)

Core molecular function — Ca2+-dependent carbohydrate (mannose) binding

GO mapping: GO:0005537 D-mannose binding (MF, verified active), GO:0030246 carbohydrate
binding (MF parent, verified), GO:0120153 calcium-dependent carbohydrate binding (MF,
verified active 2026-06; definition "capability to attach to a carbohydrate molecule when
calcium ions are present"). The Ca2+-dependent sugar binding is the defining, evolutionarily
conserved core MF; this should be the apex of core_functions rather than "protein binding".

Pattern-recognition receptor activity + complement lectin pathway

GO mapping: GO:0038187 pattern recognition receptor activity (MF, IDA); GO:0001867 complement
activation, lectin pathway (BP, IDA — strongly supported); GO:0045087 innate immune response;
GO:0042742 defense response to bacterium. These are core.

Opsonization / phagocytosis / defense (downstream effector roles)

Interactions = the MASP/MAp/regulator network (basis of "protein binding" IPI)

Most GO:0005515 "protein binding" / GO:0042802 "identical protein binding" /
GO:0048306 "calcium-dependent protein binding" IPI annotations come from a coherent body of
interaction studies, NOT from random partners:
- MASP-1, MASP-2, MASP-3, MAp19/MAp44, MAP-1 (the lectin-protease complex): PMID:11290788, 9087411, 15117939, 18177377 (calreticulin co-receptor via MASP-binding site), 19939495, 20956340 (CL-11), 21035894 (MAP-1), 21054788 (CD91/LRP1 via MASP-binding site), 22607836, 22854970 (MAP-1 structure), 25579818 (initiating complex).
- CR1 (complement receptor 1, CCP24-25): PMID:23460739, 29563915.
- Cross-talk / pentraxins: PMID:21106539 (PTX3/SAP heterocomplexes), 32041782 (CTRP6/collectin-11), 32759297 (β2-glycoprotein I).
- TLR4: PMID:21383675 (MBL binds TLR4 ectodomain, suppresses LPS-induced cytokines) — a regulatory/immunomodulatory interaction.
- SRGN serglycin: PMID:21268013 (GAG-mediated inhibition of LP). DMBT1/SALSA/gp340: PMID:22811680.
- HCV glycoproteins: PMID:21203938 (inhibits HCV entry). High-throughput interactome: PMID:32296183, 33961781 (HuRI / BioPlex; generic, low specificity).

These IPI "protein binding" terms are real but UNINFORMATIVE as MF. Per curation guidelines
they should not be the gene's representative MF. The MASP-binding interactions are best captured
in core_functions via complex membership (GO:1905370 serine-type endopeptidase complex /
ComplexPortal CPX-6170, CPX-6203) plus the carbohydrate-binding MF, rather than retained as
generic "protein binding". Action plan: MARK_AS_OVER_ANNOTATED most generic GO:0005515 IPI
(keep, but non-representative); ACCEPT/KEEP the MASP-relevant identical/Ca2+-dependent protein
binding that documents complex assembly; downgrade in core_functions toward carbohydrate binding.

Possible miscitations / careful handling

Disease / polymorphism (process-level, mostly non-core)

Structural variants in exon 1 (codon 52 R>C, 54 G>D [rs1800450], 57 G>E [rs1800451]) disrupt the
collagen helix and lower serum MBL; promoter variants modulate levels. MBL deficiency (~5% of
Europeans, ~10% sub-Saharan Africans) predisposes to infection in toddlers, neutropenic
chemotherapy and transplant patients; associations with HBV recovery, COVID-19 severity,
M. africanum TB protection [UniProt POLYMORPHISM; PMID:1675710, 1304173, 15994813, 21695215,
35102342]. These are downstream susceptibility/pleiotropy, not the core molecular function.

Core function synthesis (for review)

  1. Ca2+-dependent mannose/GlcNAc/fucose (carbohydrate) binding by the CRD — the apex MF.
    (GO:0005537 / GO:0030246 / GO:0120153)
  2. Pattern-recognition receptor activity — recognizes microbial carbohydrate PAMPs.
    (GO:0038187), located in extracellular region (GO:0005576) and at pathogen/symbiont cell
    surface (GO:0106139).
  3. Initiation of the complement lectin pathway via the MBL-MASP complex (member of a
    serine-type endopeptidase complex, GO:1905370), driving innate immune defense / opsonization.
    (GO:0001867 process; complex GO:1905370)

Validation targets

Falcon integration (2026-06-21)

FutureHouse Falcon deep-research report generated 2026-06-21 (genes/human/MBL2/MBL2-deep-research-falcon.md,
template gene_research_go_focused_compat.md). Verified its claims against the primary literature.

Findings USED (corroborated, concordant with primary literature):
- Core MF = Ca2+-dependent carbohydrate binding; substrate specificity D-mannose / GlcNAc / L-fucose /
glucose, discriminating against D-galactose (consistent with C-type-lectin 3'/4'-OH coordination).
- Domain architecture (N-terminal Cys-rich + collagen-like + neck/coiled-coil + CRD) and oligomerization
(multimers of homotrimers; higher-order assembly required for full activity); disease variants impair
oligomerization (Larsen 2004 J Biol Chem, real DOI). Reinforces my oligomer/macropattern proposed term.
- Core BP = lectin-pathway complement activation, innate defense, opsonization; MBL-MASP1/2/3 complexes.
- Explicitly flags cytoplasm / cytosol / nucleus / synapse / apoptosis-execution / pyroptosis / neuronal /
developmental roles as UNSUPPORTED, high-risk. (None of these are in the MBL2 GOA, so no action needed,
but this independently supports my REMOVE of multivesicular body and surfactant homeostasis as off-target.)
- Apoptotic-cell clearance (Nauta 2004 J Immunol) noted as a context-specific role — consistent with UniProt
RN[18] PubMed:14515269; not present in the current GOA so not annotated, recorded here as context.

Falcon citations checked: all 11 key references resolve to real, peer-reviewed published papers with valid
DOIs (Takahashi 2006, Jack 2001, Dobó 2024, Yongqing 2012, Larsen 2004, Cedzyński 2023, Mu 2020, Zhou 2016,
Andrade 2024, Bayarri-Olmos 2024, Nauta 2004). No preprint-only or unresolvable-PMID claims were found.

Findings NOT used / treated with caution:
- The report's own citation keys (e.g. "mu2020...", "nauta2004...") are not PMIDs and several of these papers
are not in our publications/ cache, so I did NOT add them as YAML supporting_text references (which require a
verbatim cached substring). The Falcon report itself is cited as a file: reference with a verbatim quote, and
flagged MEDIUM relevance / VERIFIED in reference_review.
- Mu 2020 (calreticulin/opsonophagocytosis) is in an "early vertebrate" (teleost) model — cross-species; used
only as context, not to drive a human MBL2 annotation.
- No new GO annotations were created solely on Falcon's say-so; every accepted/added term is grounded in the
primary literature and verified GO IDs.

Review outcome summary (2026-06-21)

Finishing pass (2026-09-04, PAINT no-IBA project)

Quality pass over all 79 existing_annotations entries; two remaining validation
warnings cleared; status DRAFT -> COMPLETE (validation clean, no warnings).